Document is current
Any future updates will be listed below
-
Authors
Hatta, Masato
Brock, Nicole
Hauguel, Teresa
Feng, Chenchen
Huang, Ying
Ritter, Jana M.
Hatta, Yasuko
Keller, Matthew W.
De Souza, Ivna
Hossain, Jaber
Pusch, Elizabeth A.
Rowe, Thomas
Zhang, Herg
Cui, Liyang
O’Leary, Sarah
De La Cruz, Juan A.
Johnson, Monique C.
Belser, Jessica A.
Sun, Xiangjie
Liddell, Jimma
Creech, Margaret
Rouse, Joseph R.
Carney, Paul
Chang, Jessie
Currier, Michael
Wang, Li
Kirby, Marie K.
Di, Han
Barnes, John R.
Stevens, James
Dugan, Vivien G.
Davis, C. Todd
Wentworth, David E.
Allen, Pirada Suphaphiphat
Maines, Taronna R.
Zhou, Bin
-
Funding
Funding for this research was provided by:
Centers for Disease Control and Prevention
Pfizer
- License Information
-
More Information
Article History
Received: 2 July 2025
Accepted: 7 November 2025
First Online: 29 November 2025
Competing interests
: T.H., I.D.S., H.Z., L.C., S.O., and P.S.A. are current employees of Pfizer Inc., and may, as a consequence, be shareholders. Pfizer was involved in the design, analysis, and interpretation of the data in these research studies, the writing of this report, and the decision to publish. T.H., I.D.S., and P.S.A. are inventors on patent applications relating to influenza mRNA compositions.
